GLP1R and Parkinson disease: In experimental PD models, GLP-1 receptor agonists (GLP-1RAs) can ameliorate the progression of α-syn pathology and dopaminergic neuronal loss, probably through anti-neuroinflammatory and neuroprotective effects (264).